Risks Posed by Anti-novel Coronavirus Pneumonia Drug-arbidol

doi:10.19803/j.1672-8629.2020.04.02

Abstract

Abstract: Objective To analyze the risks posed by arbidol in China in order to provide reference for clinical rational drug use. Methods Individual cases of adverse drug reactions retrieved from the WHO Vigilyze, China adverse drug reaction database, domestic and foreign literature were analyzed. Results The risks of gastrointestinal disorders, general disorders and cutaneous damage should be our concerns. Conclusion We should reinforce the safety monitoring of arbidol, update the drug labeling without delay and promote the rational application of medicines.

Key words: novel coronavirus pneumonia, arbidol, adverse reaction

CLC Number:

R969.3

WANG Tao, SONG Haibo, TIAN Chunhua. Risks Posed by Anti-novel Coronavirus Pneumonia Drug-arbidol[J]. Chinese Journal of Pharmacovigilance, 2020, 17(4): 198-201.

References

[1] 国家卫生健康委员会. 关于印发新型冠状病毒肺炎诊疗方案(试行第六版)的通知[EB/OL]. (2020-02-18)[2020-03-02].http://www.nhc.gov.cn/xcs/zhengcwj/202002/8334a8326dd94d329df351d7da8aefc2.shtml.
[2] Blaising J,Polyak SJ,Pécheur EI.Arbidol as a broad-spectrumantiviral: an update[J]. Antiviral Res,2014,107:84-94.
[3] Brooks MJ,Burtseva EI,Ellery PJ,et al.Antiviral activity ofarbidol, a broad-spectrum drug for use against respiratoryviruses, varies according to test conditions[J]. J Med Virol,2012,84(1):170-181.
[4] Liu Q,Liu DY,Yang ZQ.Characteristics of human infection withavian influenza viruses and development of new antiviralagents[J]. Acta Pharmacol Sin,2013,34(10):1257-1269.
[5] 张超,陈姝冰,张洁,等. 浅析注册用于新冠肺炎治疗的临床试验药物[J]. 药学学报,2020,CNKI网络首发论文.
[6] UMC.Uppsala Monitoring Centre[DB].https://vigilyze.who-umc.org.Accessed.
[7] 王孟昭,蔡柏蔷,李龙芸,等. 阿比朵尔治疗流行性感冒的随机、双盲、安慰剂对照、多中心临床研究[J]. 中国医学科学院学报,2004,26(3):289-293.
[8] 苏欣,谢增华,施毅,等. 阿比多尔治疗急性病毒性上呼吸道感染的随机双盲对照临床研究[J]. 临床内科杂志,2005,22(10):669-671.
[9] 刘宏博,曲文秀,李胜岐,等. 盐酸阿比朵尔片治疗流行性感冒的多中心随机双盲平行对照临床研究[J]. 中国临床药理学杂志,2006,22(6):403-405.
[10] 杜小兵,刘双,温林芳,等. 阿比多尔片治疗流行性感冒有效性和安全性的开放性临床试验研究[J]. 心肺血管病杂志,2017,36(7):518-520.
[11] 田兆兴,任乃刚,闫崴,等. 盐酸阿比朵尔干混悬剂治疗病毒性上呼吸道感染的临床研究[J]. 中国临床药理学杂志,2013,29(2):104-105.
[12] 陈致雯,卢焯明. 阿比多尔颗粒治疗儿童流行性感冒疗效观察[J].现代中西医结合杂志, 2014,23(14):1528-1529.
[13] Liu MY,Wang S,Yao WF,et al.Pharmacokinetic propertiesand bioequivalence of two formulations of arbidol: an open-label,single-dose, randomized-sequence, two-period crossover studyin healthy Chinese male volunteers[J]. Clin Ther,2009,31(4):784-792.
[14] Pshenichnaya NY,Bulgakova VA,Lvov NI,et al.Clinicalefficacy of umifenovir in influenza and ARVI (study ARBITR).Ter Arkh,2019,91(3):56-63.
[15] 康雪娜. 喜炎平注射液联合阿比多尔治疗病毒性肺炎临床疗效观察[J]. 医学理论与实践,2015,28(4):464-465.
[16] 曹瑜. 盐酸阿比多尔片在治疗急性呼吸道病毒感染中的安全性与有效性观察[J]. 中国现代药物应用,2018,12(17):101-103.
[17] 王涛,吴桂芝,董铎. 盐酸溴己新注射剂安全性风险的分析及思考[J]. 中国药物警戒, 2019,16(3):171-173.